Pregnancy achievement rates among couples using the CrMS to target fertile days are analyzed by cycle type, reproductive history, and duration of use, demonstrating the system's capacity to accommodate irregular and abnormal cycles without reducing its fertility-targeting utility. These data are foundational to NaProTECHNOLOGY's application in infertility management, establishing that the CrMS identifies fertile windows even in subfertile populations with disrupted cycle parameters.
how effective is the Creighton Model for getting pregnant, Creighton Model achieving pregnancy rate, natural family planning to conceive success rate, fertility awareness method pregnancy rate per cycle, Creighton FertilityCare conceiving in first cycle, do economic conditions affect pregnancy rates, Creighton Model use effectiveness achieve vs avoid, NaProTechnology charting to achieve pregnancy
Cite this article
Hilgers, T. W., & Stanford, J. B. (2004). Chapter 17: Achieving-Related Pregnancy Rate and Its Natural Adaptability. The Medical and Surgical Practice of NaProTECHNOLOGY, 231-240.
Hilgers TW, Stanford JB. Chapter 17: Achieving-Related Pregnancy Rate and Its Natural Adaptability. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:231-240.
Hilgers, T. W., and J. B. Stanford. "Chapter 17: Achieving-Related Pregnancy Rate and Its Natural Adaptability." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004, pp. 231-240.
Related articles
Fertility AwarenessCreighton Model FertilityCare SystemCervical Mucus BiomarkersPeak Day Identification
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The content and sequence of the introductory and follow-up instructional sessions that constitute the formal CrMS education series are outlined, covering observation technique, recording conventions, and the practitioner-client interaction model. Consistent delivery of these core instructions establishes the behavioral competence required for both family planning use and the medical monitoring applications that NaProTECHNOLOGY depends upon.
Fertility AwarenessCreighton Model FertilityCare SystemContinuous Mucus DischargeEssential Sameness Pattern and Point of Change
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Women with persistent or continuous vaginal discharges — including those from chronic cervicitis, hormonal imbalance, or other gynecologic sources — present a distinct charting challenge, and this chapter provides CrMS-specific protocols for distinguishing pathologic discharge from fertile-quality cervical mucus. Correct identification is clinically critical because misclassification distorts cycle interpretation, effectiveness calculations, and the hormone-assessment timeline.
Fertility AwarenessCervical Mucus ObservationFecundity ResearchCreighton Model
Stanford JB, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The Mucus Cycle Score, derived from the standardized CrMS daily observations, quantifies cervical mucus quality and quantity across a cycle and correlates with measured estrogen levels and fecundity rates, providing a non-invasive index of reproductive potential. Declining mucus scores are clinically actionable, directing investigation into hypoestrogenism, cervical pathology, or medication effects that reduce cycle fecundity and can be corrected before ART is considered.
NaProTECHNOLOGYCreighton Model FertilityCare SystemCervical eversion and ectropionChronic discharge charting and classification
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The Creighton Model's standardized daily vulvar observation system -- recording discharge color, consistency, quantity, and sensation -- allows chronic pathological discharges (persistent yellow or cloudy mucus, continuous post-Peak discharge, premenstrual brown bleeding, or refractory vulvovaginitis) to be distinguished from normal cyclical mucus patterns and tracked longitudinally as a diagnostic tool. NaProTECHNOLOGY uses chronic discharge patterns as biomarkers that prompt organism-specific cultures, targeted hormonal evaluation, ultrasound, and etiology-directed treatment -- including antimicrobials, cooperative hormone replacement, or fertility-sparing surgery -- rather than empirical cycle suppression.